Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.
Stocks · News reference
Celldex shares are trading lower. The company reported topline results from the Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria whose symptoms are inadequately controlled by H1-antihistamines.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.